Norgine Pedmarqsi Recall EL(26)A/42: Class 2 Action for Particulates

• Norgine Pharmaceuticals Limited has issued a Class 2 recall for specific batches of Pedmarqsi 80 mg/mL solution for infusion due to particulate matter.
• The recall, referenced as EL(26)A/42, is a pharmacy and wholesaler level action, requiring immediate cessation of supply and return of affected stock.
• No adverse reactions related to the particulate matter have been reported, and other batches of Pedmarqsi remain available for use.
• Healthcare professionals are advised to visually inspect vials before administration, as per existing instructions.
• Compliance with the MHRA directives is crucial for wholesalers and pharmacies to manage product liability and ensure patient safety.

Compliance officers within these organizations should review and confirm that internal protocols for handling such recalls are robust, clearly documented, and effectively communicated to all relevant personnel.

Norgine Pharmaceuticals Limited has initiated a Class 2 medicines recall for specific batches of its Pedmarqsi 80 mg/mL solution for infusion, identified by the reference EL(26)A/42. This urgent action stems from the detection of particulate matter within the product during routine stability investigations. The active ingredient in Pedmarqsi is sodium thiosulfate.

While the issue is currently confirmed to be limited to the two batches specified in this Norgine Pharmaceuticals Limited recall, the company has stated that investigations into all other batches are ongoing. Importantly, no adverse reactions related to the presence of particulate matter have been reported by users of the product to date. Other batches of Pedmarqsi 80 mg/mL remain available for continued use, and healthcare professionals are reminded of the existing instruction in the Patient Information Leaflet to visually inspect vial contents for any particulate matter or discoloration prior to administration, with inline filters also being an option for use with this product.

This MHRA Class 2 medicines recall is categorized as a pharmacy and wholesaler level recall, meaning that direct action by patients is not required. Pedmarqsi is typically administered by healthcare professionals within a hospital setting. The directive mandates that all recipients of the affected batches must immediately cease supplying them. Furthermore, all remaining stock of the recalled batches must be quarantined and subsequently returned to the supplier, adhering strictly to the supplier's approved return process.

NHS regional teams have been specifically requested to disseminate this information to community pharmacists and dispensing general practitioners to ensure widespread awareness and compliance. Norgine Pharmaceuticals Limited has provided contact details for medical information inquiries and stock control support, underscoring the importance of clear communication during this Norgine Pedmarqsi recall EL(26)A/42 event. Any suspected adverse reactions, despite none being reported for this specific issue, should always be reported via the MHRA Yellow Card scheme.

For pharmaceutical wholesalers, pharmacies, and hospital groups, this particulate matter drug recall UK presents significant legal and compliance considerations. Lawyers advising these entities must ensure their clients fully understand and immediately implement the MHRA directives. This includes verifying that all affected Pedmarqsi batches are promptly removed from circulation, quarantined effectively, and returned according to the specified procedures to mitigate potential product liability risks.

Compliance officers within these organizations should review and confirm that internal protocols for handling such recalls are robust, clearly documented, and effectively communicated to all relevant personnel. Adherence to this pharmacy wholesaler recall guidance is not merely a procedural step but a critical measure to uphold patient safety and avoid regulatory penalties. The sodium thiosulfate recall highlights the continuous need for vigilance in pharmaceutical supply chains and the importance of swift, decisive action in response to product quality concerns.

Lawyers advising pharmaceutical wholesalers, pharmacies, or hospital groups must ensure their clients immediately cease supplying affected Pedmarqsi batches, quarantine existing stock, and follow supplier return procedures to comply with MHRA directives and mitigate product liability risks. Compliance officers should verify internal protocols for handling such recalls are robust and documented.

Source: Original reporting via UK government's Medicines and Healthcare products Regulatory Agency